Eli Lilly antibody drug prevents illness among residents and staff of nursing homes, study finds

Nation and World News

A healthcare worker working with the Florida Department of Health in Broward administers a Pfizer-BioNtech COVID-19 vaccine to Nancy Mathews, 90, at the John Knox Village Continuing Care Retirement Community on January 6 in Pompano Beach, Florida. (Photo by Joe Raedle/Getty Images)

Drugmaker Eli Lilly said Thursday its COVID-19 antibody drug can prevent illness in residents and staff of nursing homes and other long-term care locations.

It’s the first major study to show such a treatment may prevent disease.

Residents and staff who got the drug had up to a 57% lower risk of getting COVID-19 compared to others at the same facility who got a placebo, the drugmaker said. Among nursing home residents only, the risk was reduced by up to 80%.

The study involved more than 1,000 residents and staff at nursing homes and other long-term care locations. The research was conducted with the National Institutes of Health. Results were released in a press release and the company said it would publish results in a journal soon.

The Food and Drug Administration in November allowed emergency use of Lilly antibody drug as a treatment for mild or moderate cases of COVID-19 that do not require hospitalization. It’s a one-time treatment given through an IV.

Lilly said it will seek expansion of that authorization to include using the drug to prevent and treat COVID-19 in long-term care facilities.

Nursing homes and other long-term care locations have been hard hit by the pandemic. In the United States, they account for less than 1% of the population, but nearly 40% of deaths from COVID-19.

These long-term care locations have been given priority to vaccinate residents and staff with recently authorized COVID-19 vaccines.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP!

Click for latest news and information

TRENDING HEADLINES

Join our daily newsletter!